N4 Pharma PLC Result of Broker Offer and Total Voting Rights (2250H)
23 Noviembre 2022 - 1:44AM
UK Regulatory
TIDMN4P
RNS Number : 2250H
N4 Pharma PLC
22 November 2022
22 November 2022
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Broker Offer
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that, further to the announcement made on
18 November 2022, the Broker Offer, a facility to allow existing
shareholders and other interested parties to participate on the
same terms to the Placing announced on 18 November 2022, has now
closed having raised a gross amount of GBP54,000, resulting in the
issue by the Company of an additional 2,700,000 new ordinary shares
of 0.4 pence each ("Broker Offer Shares").
Broker Warrants
As part of its fee, TPI will be issued with warrants ("Broker
Warrants") to subscribe for 3,162,000 new ordinary shares
exercisable at the Issue Price of 2 pence each, equivalent to 6
(six) per cent. of the gross aggregate value of funds raised in the
Placing and Broker Offer. The Broker Warrants have a term of 36
months from the date of admission of the Broker Offer Shares to
trading on AIM and are being issued under the Company's existing
share authorities.
Application for Admission
Application has been made for the Broker Offer Shares to be
admitted to trading on AIM ("Admission") and it is expected that
Admission will take place at 8.00 a.m. on or around 25 November
2022. The Broker Offer Shares will rank pari passu with the
Company's existing ordinary shares.
Total Voting Rights
Following Admission of the Broker Offer Shares, the enlarged
issued share capital of the Company will comprise 233,780,349
ordinary shares of 0.4 pence each. The Company does not hold any
ordinary shares in treasury. Consequently, 233,780,349 is the
figure which may be used by shareholders as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure and Transparency Rules.
Terms and definitions in this notification are as defined in the
notification of 18 November 2022.
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement via Regulatory
Information Service, this inside information is now considered to
be in the public domain.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
James Pope
IFC Advisory Ltd Tel: +44(0)20 3934
6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through preclinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAEFAALPAFFA
(END) Dow Jones Newswires
November 22, 2022 05:50 ET (10:50 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024